22 Feb 2022 , 02:05 PM
Marksans Pharma announced that UK MHRA has granted Market Authorisation to the Companys wholly owned subsidiary Bell Sons & Co. (Druggists) for Bells Healthcare All in One Oral Solution.
Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg.
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs. This is the first generic approval by UK MHRA for the product.
Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) in UK.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
